评估海洋氧载体HEMO2life®用于肾移植器官保存的疗效(OxyOp2):多中心随机试验研究方案
OxyOp2为前瞻性、多中心、随机、对照、单盲、平行组研究,在肾移植中对比标准治疗与在常规保存液中加用HEMO2life®(剂量1 g/l保存液)的器官保存效果,主要结局为移植后第一周需肾脏替代治疗定义的移植物功能延迟恢复。
要点
- OxyOp2在肾移植中评估HEMO2life®加用于保存液的器官保存效果。
- 同一供者的两颗肾脏随机分入标准治疗组与HEMO2life®组。
- 主要结局为移植后第一周需肾脏替代治疗的移植物功能延迟恢复。
核心结论
- OxyOp2旨在在大样本肾移植人群中确证并量化HEMO2life®用于器官保存的疗效。
研究设计与样本
- OxyOp2为前瞻性、多中心、随机、对照、单盲、平行组研究,对照为标准治疗。
- 按纳入/排除标准选择合适供者后,同一供者的两颗肾脏均纳入研究。
- 根据供者特征,两颗肾脏分别采用静态冷保存(标准供者)或机器灌注(扩展标准供者及心脏死亡后供者)。
- 同一供者的两颗肾脏随机分配:一颗进入标准治疗组(按当地常规使用保存液保存),另一颗进入活性治疗组(在常规保存液基础上加用HEMO2life®)。
- HEMO2life®以1 g/l保存液的剂量用于离体移植物保存。
主要发现
- OxyOp试验显示,使用氧载体HEMO2life®保存的器官移植物功能延迟恢复显著更少。
关键数值与推荐
- 主要结局为移植物功能延迟恢复的发生,定义为移植后第一周内需要肾脏替代治疗。
- HEMO2life®在离体移植物保存中的剂量为1 g/l保存液。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preventing ischemia‒reperfusion injury (IRI) is a major issue in kidney transplantation, particularly for transplant recipients receiving a kidney from extended criteria donors (ECD). The main consequence of IRI is delayed graft function (DGF). Hypoxia is one of the key factors in IRI, suggesting that the use of an oxygen carrier as an additive to preservation solution may be useful. In the OxyOp trial, we showed that the organs preserved using the oxygen carrier HEMO2life® displayed significantly less DGF. In the OxyOp2 trial, we aim to definitively test and quantify the efficacy of HEMO2life® for organ preservation in a large population of kidney grafts. METHODS: OxyOp2 is a prospective, multicenter, randomized, comparative, single-blinded, parallel-group study versus standard of care in renal transplantation. After the selection of a suitable donor according to the inclusion/exclusion criteria, both kidneys will be used in the study. Depending on the characteristics of the donor, both kidneys will be preserved either in static cold storage (standard donors) or on machine perfusion (for ECD and deceased-after-cardiac-death donors (DCD)). The kidneys resulting from one donor will be randomized: one to the standard-of-care arm (organ preserved in preservation solution routinely used according to the local practice) and the other to the active treatment arm (HEMO2life® on top of routinely used preservation solution). HEMO2life® will be used for ex vivo graft preservation at a dose of 1 g/l preservation solution. The primary outcome is the occurrence of DGF, defined as the need for renal replacement therapy during the first week after transplantation. DISCUSSION: The use of HEMO2life® in preservation solutions is a novel approach allowing, for the first time, the delivery of oxygen to organs. Improving graft survival by limiting ischemic lesions is a major public-health goal in the field of organ transplantation. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT04181710 . registered on November 29, 2019.
引用
- Le Meur Y, Nowak E, Barrou B, et al. Evaluation of the efficacy of HEMO2life®, a marine OXYgen carrier for Organ Preservation (OxyOp2) in renal transplantation: study protocol for a multicenter randomized trial. Trials. 2023. PMID: 37127632. doi:10.1186/s13063-023-07302-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。